* Encouraging ACV growth and margins * Small sales revisions, but '26e-'27e EBIT up 29-28% on lower ...
* Strategic pivot into the SOFC market * Rights issue of ~SEK 87.
Redeye comments on the new orphan drug designation for the treatment of Osteogenesis Imperfecta from...
Vi inleder bevakning på Beyond Frames, en svensk spelutvecklare och publisher inom XR, en samlingste...
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and the recent Re...
Redeye comments on yesterday’s cash offer of SEK45 per share from Aneo.
European Commission draft, suggests a non-renewal for Selektope under EU BPR, which now seems as the...
Redeye provides an in-depth update on AcouSort following the company’s Q3 report.
Redeye visited Cheffelo’s Mölnlycke facility, where Linas Matkasse’s meal kits are produced.
Redeye comments on Polygiene's CEO shift that was announced today.
Case Group rapporterade sitt starkaste kvartal någonsin med stark tillväxt, stabila kapitalflöden oc...
Redeye comments on Iconovo’s announcement of a directed share issue and a fully guaranteed rights is...
Redeye takes a positive stance towards Hexatronic’s US Data Center acquisition, adding geographical ...
Redeye provides an updated valuation of Alligator as the subscription price in the rights issue, SEK...
* Q3: high GM, but soft device sales and ARPU * Doro conversion rate 25% in D2C channels (13% in Q2)...
Redeye comments on Surgical Science dropping an absolute bomb of a press release.
Redeye comments on the recently announced continuing restructuring of the Wellness division, which r...
* ~SEK 26m defence order announced earlier today * Backlog of ~SEK 390m * Provides additional visibi...
Insplorion has announced that the ATEX certification process will be delayed by another estimated th...
